ArticleAntimicrobial agents and chemotherapy2003
Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Trial
- Delafloxacin: what does a new fluoroquinolone offer?Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Strategic re-engineering of antibiotics.Nature reviews bioengineering · 2025Article
- Updated Review on Clinically-Relevant Properties of Delafloxacin.Antibiotics (Basel, Switzerland) · 2023Review
- Article
- Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline.Antibiotics (Basel, Switzerland) · 2021Review
- Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.European journal of drug metabolism and pharmacokinetics · 2019Review
- DelafloxacinJournal of clinical microbiology · 2018Article
- Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.Infection and drug resistance · 2018Review
- New Horizons in Mycoplasma genitalium Treatment.The Journal of infectious diseases · 2017Review
- Article
- Delafloxacin: design, development and potential place in therapy.Drug design, development and therapy · 2017Review
- In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.Antimicrobial agents and chemotherapy · 2016Article
- Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.The Journal of antimicrobial chemotherapy · 2011Article
- Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy.Drug, healthcare and patient safety · 2011Article
- The presence of Mycoplasma hominis in isolates of Trichomonas vaginalis impacts significantly on DNA fingerprinting results.Parasitology research · 2008Article
- Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.Drugs · 2008Review
- Review
- Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates.Journal of veterinary science · 2006Article
- In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.Antimicrobial agents and chemotherapy · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We determined in vitro susceptibilities for ABT-492 and other antimicrobials against Mycoplasma pneumoniae, Mycoplasma fermentans, Mycoplasma hominis, and Ureaplasma species. ABT-492 MICs were < or =1 microg/ml, and the agent was bactericidal against selected isolates of M. pneumoniae and M. hominis. ABT-492 has potential for treatment of infections due to these microorganisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.